- Trials with a EudraCT protocol (173)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
173 result(s) found for: Tertiary treatment.
Displaying page 1 of 9.
EudraCT Number: 2022-001023-32 | Sponsor Protocol Number: RACE_01 | Start Date*: 2022-09-14 |
Sponsor Name:Medical University of Vienna | ||
Full Title: The effect of epinephrine, norepinephrine and phenylephrine on intraoperative hemodynamic performance - a prospective double-blinded, randomized clinical trial | ||
Medical condition: Patients > 45 years of age at-risk for cardiovascular complications undergoing moderate- to high-risk major open abdominal surgery. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2020-000656-35 | Sponsor Protocol Number: 73042 | Start Date*: 2020-09-09 |
Sponsor Name:Radboud University Medical Centre | ||
Full Title: The inflammatory response of monocytes and neutrophils to Crystals after Low dose colchicine in patients with coronary artery disease | ||
Medical condition: Atherosclerosis | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2021-001069-20 | Sponsor Protocol Number: HIDROGUM21 | Start Date*: 2022-01-12 |
Sponsor Name:Vall d'Hebron Hospital Universitari | ||
Full Title: Tolerability and acceptance of two oral hydrocortisone compounding formulation for pediatrics | ||
Medical condition: Adrenal hyperplasia or isolated primary adrenal insufficiency or panhypopituitarism (secondary or tertiary adrenal insufficiency) | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2015-005757-12 | Sponsor Protocol Number: FAIR-HFpEF | Start Date*: 2017-06-06 |
Sponsor Name:Charité – Universitätsmedizin Berlin | ||
Full Title: Effect of IV iron (ferric carboxymaltose, Ferinject) on exercise tolerance, symptoms and quality of life in patients with heart failure with preserved ejection fraction (HFpEF) and iron deficiency ... | ||
Medical condition: Patients with heart failure with preserved ejection fraction (HFpEF) and iron deficiency (ID) with and without anaemia | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2021-000580-78 | Sponsor Protocol Number: EMPAtia | Start Date*: 2022-02-02 |
Sponsor Name:The Children’s Memorial Health Institute | ||
Full Title: "The assessment of effectiveness and safeness of utilizing empagliflozin in the treatment of neutropenia of patients suffering from glycogenolysis type Ib" | ||
Medical condition: neutropenia and / or abnormal neutrophil function in glycogenosis I b | ||
Disease: | ||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |
Trial protocol: PL (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2005-005135-10 | Sponsor Protocol Number: 2005-151 | Start Date*: 2006-01-19 |
Sponsor Name:Jeppe Hagstrup Christensen | ||
Full Title: Omacor; omega-3-acid ethyl ester 90 (N-3 PUFA) and risk faktors in HIV infected patients treated with HAART with special focus on lipids | ||
Medical condition: Several investigations show that HIV infected patients have a higher risk for development of heart disease if treated with HAART. The investigation will evaluate the effect of fish oil on blood ... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DK (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2014-002998-11 | Sponsor Protocol Number: ENDO-RCA | Start Date*: 2014-11-14 | |||||||||||
Sponsor Name:Rigshospitalet, Capital Region Bloodbank 2034, Section for Transfusion Medicine | |||||||||||||
Full Title: Safety and efficacy of low-dose Iloprost administration and blood pressure target in addition to standard therapy, as compared to standard therapy alone, in post-cardiac- arrest-syndrome patients... | |||||||||||||
Medical condition: Cardiac Arrest | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-004592-35 | Sponsor Protocol Number: 6836 | Start Date*: 2010-06-16 |
Sponsor Name:Barts Health NHS Trust | ||
Full Title: A Randomised Stratified Multicentre Phase II Clinical Trial of Single-Agent ADI-PEG 20 (Pegylated Arginine Deiminase) in Patients with Malignant Pleural Mesothelioma. | ||
Medical condition: Mesothelioma | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2020-002459-40 | Sponsor Protocol Number: BREAST-AB-01 | Start Date*: 2020-12-17 |
Sponsor Name:Rigshospitalet | ||
Full Title: Prophylactic treatment of breast implants with a solution of gentamicin, vancomycin and cefazolin antibiotics for women undergoing breast reconstructive surgery: a randomized controlled trial (The ... | ||
Medical condition: Implant-based breast reconstruction following mastectomy | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Female | |
Trial protocol: DK (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2011-002175-42 | Sponsor Protocol Number: GernerDex001 | Start Date*: 2011-10-12 |
Sponsor Name:Paracelsus Medizinische Universität - Universitätsklinik für Anästhesie | ||
Full Title: The effect and safety of dexmedetomidine as an additive to ropivacaine for interscalene brachial plexus blocks for shoulder surgery | ||
Medical condition: The goal of the present study is to investigate the safety and efficiacy of dexmedetomidine added to ropivacaine for interscalene brachial plexus nerve block for shoulder surgery in humans. Provi... | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: AT (Completed) | ||
Trial results: View results |
EudraCT Number: 2010-023980-17 | Sponsor Protocol Number: Metformin 3.0 | Start Date*: 2011-08-24 |
Sponsor Name:St. Antonius Hospital | ||
Full Title: An efficacy, safety and pharmacokinetic study on the short-term and long-term use of METFORMIN in obese children and adolescents | ||
Medical condition: obese children and adolescents of Caucasian descent with insulin resistance in the age of ≥ 10 and ≤ 16 years at study entry. | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2004-005184-15 | Sponsor Protocol Number: 05_ENDO_46 | Start Date*: 2005-05-24 |
Sponsor Name:Christie Hospital NHS Trust | ||
Full Title: Central Hypothyroidism and Adjusted Thyroxine dose Study (CHATS): impact of increasing free thyroxine levels in patients with hypopituitarism | ||
Medical condition: Central (secondary/tertiary) hypothyroidism (subclinical) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2019-004070-26 | Sponsor Protocol Number: BRICE | Start Date*: 2021-08-02 | |||||||||||
Sponsor Name:FONDAZIONE RICERCA TRASLAZIONALE (FORT) | |||||||||||||
Full Title: A Phase 1/2 Study Exploring Safety, Tolerability and Efficacy of BRIgatinib in Combination With CEtuximab in Subjects With Advanced EGFR mutated or ALK or ROS1 positive Non-Small Cell Lung Cancer a... | |||||||||||||
Medical condition: Advanced or metastatic epidermal growth factor receptor (EGFR) mutation positive non-small cell lung cancer (NSCLC) with acquired resistance to approved EGFR tyrosine kinase inhibitors (TKI); advan... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-001923-11 | Sponsor Protocol Number: Nef-202 | Start Date*: 2012-10-17 | |||||||||||
Sponsor Name:Pharmalink AB | |||||||||||||
Full Title: A Multicentre, Interventional Treatment, Randomised, Double-Blind, Single Group Assignment, Placebo Controlled Study to Evaluate the Efficacy and Safety of Two Different Doses of Nefecon® in Primar... | |||||||||||||
Medical condition: Primary IgA nephropathy patients at risk of developing end stage renal disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FI (Completed) CZ (Completed) DE (Completed) BE (Completed) SE (Completed) DK (Completed) IT (Completed) GB (Completed) NL (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-002224-15 | Sponsor Protocol Number: | Start Date*: 2009-01-09 |
Sponsor Name:Göteborgs Universitet | ||
Full Title: Individual GH dosing using 1st year GH responsiveness for prepubertal growth response in short GHD/ISS children | ||
Medical condition: GHD+ISS in prepubertal children born at term or prematurely, AGA or SGA GHD and SGA children (phase IV study) ISS children (phase III study) | ||
Disease: | ||
Population Age: Children, Under 18 | Gender: Male, Female | |
Trial protocol: SE (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2010-018435-18 | Sponsor Protocol Number: P01432 | Start Date*: 2010-05-21 |
Sponsor Name:Papworth Hospital NHS Foundation Trust | ||
Full Title: Assessing Platelet Inhibitory Response to Clopidogrel – Feasibility, Safety and Cost Analysis of a Tailored Platelet Inhibition Strategy for Elective PCI Patients | ||
Medical condition: To investigate the feasibility, safety and cost of using the platelet assay VerifyNow-P2Y12 to guide optimal P2Y12 platelet inhibition in patients undergoing elective PCI, compared with standard tr... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2007-002976-32 | Sponsor Protocol Number: unknown | Start Date*: 2007-09-06 |
Sponsor Name:TIPharma | ||
Full Title: COBRA-light study, an open randomised trial comparing a modified COBRA therapy with the COBRA therapy according to BeSt in early rheumatoid arthritis. | ||
Medical condition: Patients with early rheumatoid arthritis wil be treated with a combination therapy: COBRA according to BEST or a modified COBRA schedule (COBRA-light). | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2011-002203-15 | Sponsor Protocol Number: PregMet2 | Start Date*: 2012-08-08 | |||||||||||
Sponsor Name:NTNU, Norwegian University of Science and Technology | |||||||||||||
Full Title: Metformin treatment of pregnant PCOS women and prevention of late miscarriages and preterm birth The PregMet 2 Study | |||||||||||||
Medical condition: Poly Cystic Ovarial Syndrome (PCOS) in pregnant women. PCOS should be diagnosed according to the Rotterdam Consensus criterias: - at least 2 out of 3 criterias 1.PCO in at least one ovary 2.Olig... | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: NO (Completed) SE (Completed) IS (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-001331-26 | Sponsor Protocol Number: PROLIFIC2020 | Start Date*: 2020-04-14 | |||||||||||
Sponsor Name:Cambridge University Hospitals NHS Foundation Trust | |||||||||||||
Full Title: ChemoPROphyLaxIs For covId-19 infeCtious disease (the PROLIFIC trial) | |||||||||||||
Medical condition: Coronavirus disease 2019 (COVID-19) caused by the infection, SARS-CoV-2 | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-007407-86 | Sponsor Protocol Number: LevoRep | Start Date*: 2009-09-14 | |||||||||||
Sponsor Name:Medizinische Universität Innsbruck - Universitätsklinik für Innere Medizin III | |||||||||||||
Full Title: Efficacy and safety of pulsed infusions of levosimendan in outpatients with advanced heart failure | |||||||||||||
Medical condition: Chronic heart failure | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Completed) GR (Completed) DE (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
